KKR will pay $5.7 billion in cash to take Integer Holdings private, acquiring one of the largest independent suppliers of batteries, components, and subassemblies to the global medical device industry. The deal prices Integer at a premium to recent trading levels and removes a critical supply-chain node from public scrutiny. Integer manufactures power systems for implantable cardiac devices, neurostimulators, and surgical tools — components that end up inside products from Medtronic, Abbott, and Boston Scientific. The company reported $1.53 billion in revenue for the twelve months ending June 2026, with operating margins in the mid-teens.
KKR has been methodical in healthcare verticals where regulatory moats and switching costs protect returns. Integer fits cleanly: long customer contracts, high technical barriers to entry, and a product mix weighted toward devices with multi-year approval cycles. The firm already owns stakes in Envision Healthcare and Heartland Dental, both plays on fragmented provider networks. Integer is different — this is upstream consolidation, control over manufacturing capacity that the device majors need but prefer not to own. The supply-chain stress of 2023-2024 made these assets more valuable. Integer's largest customers cannot easily replace its battery technology or retool their devices mid-cycle.
The timing reflects two trends. First, private equity is moving capital back into hard assets with cash flow visibility, away from growth-stage bets that require multiple expansion. Integer generates steady EBITDA and serves an end market — implantable medical devices — that grows with demographics, not sentiment. Second, public medtech suppliers have been mispriced. Integer traded below 12x forward EBITDA before the announcement, a discount to both device manufacturers and contract manufacturers in adjacent sectors. KKR is paying closer to 14x, a modest premium that reflects replacement cost and customer lock-in. The deal removes earnings volatility from quarterly scrutiny and allows longer reinvestment horizons in R&D and capacity.
Operators should watch for follow-on moves in the medical component supply chain. Integer's two closest public peers — Greatbatch was taken private in 2021, and Nuvectra was acquired in 2020 — are already off the board. If KKR consolidates adjacent manufacturers or component suppliers under Integer's management, the company becomes a more valuable counterparty to the device majors and a harder asset to replicate. Allocators should note that this deal likely prices at a 4.5-5.0% unlevered yield on normalized EBITDA, with debt likely in the 4.5x-5.0x range. The refinancing window for healthcare buyouts has reopened as credit spreads tightened in Q2 2026. Expect KKR to lock in long-term financing before the Federal Reserve's next rate decision in September.
Integer's customer base is concentrated but durable. The top ten customers represent roughly 70% of revenue, and switching costs are high due to FDA approval requirements and multi-year validation cycles. KKR inherits a business where the largest risk is customer consolidation — if Medtronic or Abbott acquire smaller device makers, Integer's revenue concentrates further. The counter-risk is that regulatory complexity and capital intensity keep the device industry fragmented, preserving Integer's role as the neutral supplier. The deal closes in Q4 2026, subject to regulatory clearance and shareholder approval. Integer's board has already recommended acceptance.